Subscribe to our newsletter.
The KRAS gene is often scrutinized in the context of various cancers, including lung, colorectal, and pancreatic cancer. Mutations in this gene are key indicators that not only assist in diagnosis but also have significant implications for treatment options. For instance, the presence of a KRAS mutation can make certain therapies less effective, requiring an alternative treatment strategy. Because KRAS mutations are relatively common in specific cancer types, testing for these mutations is a standard practice in oncology. Thus, understanding the KRAS mutation status is crucial for clinicians to provide the most targeted and effective treatment for patients.